LBA53 ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib

Z. Piotrowska(Massachusetts General Hospital), M-J. Ahn(Samsung Medical Center), Y.K. Pang(University of Malaya), S.H. How(International Islamic University Malaysia), S-W. Kim(Asan Medical Center), P.J. Voon(Sarawak General Hospital), D.L. Cortinovis(Azienda Ospedaliera San Gerardo), J. De Castro Carpeño(Hospital Universitario La Paz), M. Tiseo(University of Parma), D. Rodriguez Abreu(Universidad de Las Palmas de Gran Canaria), S.S. Ramalingam(Emory University), J. Li(AstraZeneca (United States)), L. Servidio(AstraZeneca (United States)), S. Sadow(AstraZeneca (United States)), R.J. Hartmaier(AstraZeneca (United States)), B.C. Cho(Yonsei University)
Annals of Oncology
September 1, 2022
Cited by 21

Abstract


Related Papers

No related papers found

Powered by citation graph analysis